Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. It has a portfolio of eight clinical-stage product candidates. One of them, sacituzumab govitecan, has received Breakthrough Therapy Designation from FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease. Additional information on the Company can be accessed at www.immunomedics.com.